Dr. Zhang on frontline treatment selection factors in metastatic kidney cancer

“We use a lot of clinical characteristics, but I’m hopeful we will start to go into more molecular typing and gene signatures,” says Tian Zhang, MD.

Tian Zhang, MD, associate professor at UT Southwestern Medical Center, discusses factors she uses in the clinic to decide among the evolving treatment options in the frontline setting for patients with metastatic renal cell carcinoma.

Related Videos
hospital corridor
Andrew Wood, MD, answers a question during a Zoom interview
hospital hallway
Illustration of kidney cancer
Laura Bukavina, MD, MPH, and Sarah P. Psutka, MD, MS, are interviewed on Zoom by Ben Saylor from Urology Times
Cross section of human kidney
Related Content
© 2023 MJH Life Sciences

All rights reserved.